BTIG initiated coverage on Vicarious Surgical with a new price target
$RBOT
Industrial Specialties
Health Care
BTIG initiated coverage of Vicarious Surgical with a rating of Buy and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $16.00 → $7.00 | Overweight → Neutral | Piper Sandler |
| 1/7/2022 | $16.00 | Outperform | Credit Suisse |
| 12/7/2021 | $15.00 | Outperform | Cowen & Co. |
| 11/5/2021 | $15.00 | Buy | Canaccord Genuity |
| 10/18/2021 | $15.00 | Buy | BTIG |
| 10/7/2021 | $16.00 | Overweight | Piper Sandler |
10-Q - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2025. "Leading Vicarious Surgical from its earliest days through key development milestones has been an extraordinary experience. I'm incredibly proud of the foundation we've built. As I move into the role of President, I'm pleased to welcome Stephen as CEO," said Adam Sachs, President, Co-Founder, and Board member. "His depth of experienc
Adam Sachs, Co-Founder, to Remain on as President Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the "Board"), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the second quarter ended June 30, 2025 after the market closes on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 572850. A live and archived webcast of the event will be available at https://inves
Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously
Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00
Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a
Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2025. "Leading Vicarious Surgical from its earliest days through key development milestones has been an extraordinary experience. I'm incredibly proud of the foundation we've built. As I move into the role of President, I'm pleased to welcome Stephen as CEO," said Adam Sachs, President, Co-Founder, and Board member. "His depth of experienc
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the second quarter ended June 30, 2025 after the market closes on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 572850. A live and archived webcast of the event will be available at https://inves
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)